Livedoid Vasculopathy
Sometimes miscalled livedoid "vasculitis"; associated with atrophie blanche
A thrombo-occlusive disease of the small blood vessels of the skin — a clotting disorder, not a true vasculitis (inflammation of the vessel wall). Fibrin- and platelet-rich clots form inside the tiny vessels of the skin, usually on the lower legs, ankles, and feet, choking off the blood supply to the skin above them. The result is painful, slow-to-heal ulcers that eventually scar into smooth, porcelain-white patches called atrophie blanche. It is strongly linked to hypercoagulable states — blood that clots too readily — and to venous congestion in the legs.
The Anatomy — in Plain Terms
The small vessels feeding the skin clot shut. The skin above them stops getting oxygen and nutrients — it suffocates, starves, and breaks open into a wound. And that wound won't heal, because nothing living is reaching it anymore. When it finally does close, it leaves a smooth white scar behind.
It favors the lower leg, ankle, and foot — exactly where blood already has the hardest time getting back out. That's the tell: this is a disease of stalled, clot-prone blood, so it lands where the blood pools.
Source
Definition adapted from Bilgic A, et al., "A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy" (National Library of Medicine, PMC) — a peer-reviewed clinical review.
Key Points
- It is a clotting problem, not an inflammatory one — an occlusive vasculopathy without vasculitis. That is why anti-clotting therapy, not steroids, is the mainstay of treatment.
- Its hallmarks: painful ulcers on the lower legs/ankles/feet, a net-like purple mottling of the skin (livedo racemosa), and white star-shaped scars (atrophie blanche).
- It is frequently tied to hypercoagulable states and to venous hypertension and stasis — the blood pooling that comes from obstructed venous outflow.
- Diagnosed by history, exam, and a skin biopsy showing fibrin and thrombosis in the vessels without the inflammation of a true vasculitis; a clotting workup is part of the evaluation.
- The wounds are notoriously chronic — they persist for months and recur — because the underlying clotting keeps choking off the blood the healing tissue needs.
On AbilityForge
This is the disease that put the wounds on Michael Kissling's leg — and, arguably, the proof his stent was owed. His blood already clotted too readily, and May-Thurner syndrome had the venous outflow from his left leg backed up and stalling. That same stalled, clot-prone blood clotted the tiny vessels of his skin: livedoid vasculopathy. The ulcers that followed weren't a separate misfortune — they were the skin-level signature of the exact venous failure the stent existed to relieve.
Which is where the insurer's logic collapses on itself. UHC's own criteria required non-healing wounds before it would cover the stent. But non-healing wounds are the sign the venous disease has already advanced to tissue breakdown — the point at which the stent is partly too late. They demanded the catastrophe as the ticket to the thing that prevents it.
You timber a mineshaft to keep it from caving in. Requiring the cave-in first, as proof you needed the timber, isn't a coverage policy — it's the collapse, by design.
See Also